Purchasing a pipeline – perils, pitfalls, and priorities in asset acquisition
Checkpoint inhibitors. Genetic therapies. Biomarker therapies. To hear big pharma tell it, we are living in an age of medical wonders.
The problem? In some patients, they make a huge difference. In others, they don’t work at all.
From a bench-science standpoint, that’s fascinating. But if you’re a pharmaceutical executive thinking seriously about pipeline asset acquisition, translating large-molecule science into high-profit marketability is fraught with complexity.
In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.
Big pharma pipelines are not what they used to be
The majority of new drugs measure their success in increments.
Orphan drugs and tightly targeted MOAs offer the most exciting breakthroughs, but they offer them to smaller and smaller groups of patients. New cancer drugs are launched with great fanfare even when their pivotal studies suggest they offer a scant three months’ improvement over the competition. Small molecules are languishing. Biologics, once heralded as an arena of unbounded promise, are nearing the end of their patent lives, negotiating payments worth millions to keep biosimilars off the market.
You may also be interested in…
The Migraine unveiling: Bringing the invisible disability to light
Globally, headache disorders affected approximately 40% of the population, or 3.1 billion people in 2021. A migraine attack goes beyond a severe headache; it is a constellation of symptoms that may include neck pain, nausea, dizziness, visual disturbances and sensitivity to light, sounds and smell among a variety of other manifestations.
Applications of AI in Pharma and the Life Sciences industry
Decoding the use of ChatGPT - and similar LLM applications - after the dust settles: Applications of AI in Pharma and the Life Sciences industry
World Brain Day 2024
Established by the World Federation of Neurology in 2014, World Brain Day seeks to raise public awareness on various neurological health topics each year. This year’s theme, “Brain Health and Prevention”, brings awareness to preventive measures that can alleviate the burden of many neurological conditions for patients across the world.
World Kidney Cancer Day: The future of RCC treatment
World Kidney Cancer Day brings much needed attention to a disease affecting hundreds of thousands of people worldwide.